can for 12 cycles. MRI performed in July 2013 showed 2 small areas of enhancement in the left paracentral lobule in the surgical cavity as well anteriorly in the left frontal lobe both within the treatment field, which remained stable in August 2013 and enlarged slightly in November 2013 (not shown). It was unclear at the time whether this represented recurrence or treatment-related inflammatory changes. In December 2013, the patient presented with sudden-onset numbness and weakness in the right fourth and fifth digits and was found to have a new, right pronator drift. Brain MRI showed that the enhancing area in the left frontal lobe had increased to 3 cm with extensive perilesional edema causing midline shift and subfalcine herniation ( Fig. 4A and B) . MR multivoxel spectroscopy was performed the following day and showed no definitive intralesional increased vascularity (Fig. 4C) , prominent lactate peaks in lesional and perilesional regions, and elevated choline levels at the posterior medial aspect of the enhancing lesion. This pattern was considered to be consistent with a diagnosis of treatment-related inflammatory changes rather than recurrence of disease. The patient's symptoms resolved after he received dexamethasone, and he completed his chemotherapy regimen in January 2014. MRI in late January 2014 demonstrated significant improvement in the size of the enhancing lesion, perilesional edema, and mass effect. In April 2014, the patient experienced a generalized tonic-clonic seizure followed by frequent focal partial seizures and recurrence of his right-sided numbness and weakness. MRI was performed and showed an increase in the size of the lesion with significant surrounding FLAIR signal ( Fig. 4D and E) . MR perfusion now showed increased perfusion in the posterior aspect of the lesion, raising suspicion for recurrence of the metastatic disease (Fig. 4F) . A subsequent stereotactic biopsy performed via open craniotomy confirmed radiation necrosis with no evidence of disease (Fig. 5) . Although no formal cognitive testing was performed, care workers and clinicians (including a pediatric neurologist) consistently noted the achievement of developmental milestones and the absence of cognitive and motor delays. As of last follow-up in December 2014, the patient was found to have no clinical or radiographic evidence of disease, resolving radiation necrosis, and no apparent neurocognitive longterm side effects from radiation therapy.
discussion
Ewing sarcoma is a rare bone tumor of neuroectodermal origin. Marsa and Johnson first described isolated metastases to the CNS in 1971, and their hypothesis was that systemic chemotherapeutic suppression allowed the CNS micrometastases time to grow and present clinically. 10 Mehta and Hendrickson reported that 15 of 27 (56%) patients with Ewing sarcoma had neurological signs and symptoms presumed to be caused by CNS metastases. 11 The conclusion drawn at the time was that patients with Ewing sarcoma would benefit from prophylactic radiation and chemotherapy to these "sanctuary" sites. This paradigm was challenged by larger reviews of patient registries with a focus on imaging-or autopsy-proven metastasis. A review of 134 patients with Ewing sarcoma showed evidence of CNS metastasis in 3 patients (2.2%), and in all cases there was evidence of widespread metastasis before the CNS was involved. 7 A later retrospective review of 445 patients treated at the National Cancer Institute and the Intergroup Ewing's Sarcoma Study showed that true CNS metastasis occurred in 10 patients (2.2%) and that the CNS was the site of first relapse in 3 (0.7%). 17 Trigg et al. showed that the lifetime risk of CNS involvement in a patient with Ewing sarcoma was approximately 10%, and that the incidence was not affected by prophylactic radiation therapy or intrathecal methotrexate. 18 Given this, our patient was neither treated prophylactically nor screened regularly for CNS metastasis in the absence of any other signs of disease in the body. Prior case reports of radiotherapy for CNS metastases from Ewing sarcoma are summarized in Table 1 . Three notable cases reported long-term survival after GTR with adjuvant chemoradiation therapy, with no evidence of disease at 19 months or at 3.4 and 11 years of follow-up. 8, 12, 13 Radiation therapy has traditionally been external-beam wholebrain radiation therapy (WBRT) of a dose between 30 and 60 Gy, and occasionally with a local boost. 13, 15 However, Krasin et al. showed that 3D conformal radiation therapy and intensity-modulated radiation therapy with limited margins (clinical tumor volume based on a 2.0-cm margin around the gross tumor volume) were adequate treatment options for nonrhabdomyosarcoma soft-tissue sarcomas. 9 On this basis, a decision was made to limit treatment of the patient's isolated metastases to a 3D conformal plan with limited margins.
The presence of symptomatic radiation necrosis in our patient after hypofractionated partial-brain radiotherapy warrants a review of the literature to identify potential future avoidance strategies. Aoki et al. provided one of the earliest series regarding hypofractionated radiotherapy for previously unresected or radiation-treated brain metastases. 3 Among 45 patients treated with 18-35 Gy in 3-5 fractions, there were no cases of radiation necrosis in this series. Two subsequent studies further refined the treatment approach. The first identified 42 patients (22 of whom had metastases resected and 22 of whom underwent prior radiotherapy) compared several hypofractionated radiotherapy schedules. 5 The symptomatic radiation necrosis rate was noted for 3 patients (7%), but whether these patients had received prior radiotherapy was not specified. The authors ultimately recommended 30 Gy in 5 fractions as the future standard for hypofractionated radiotherapy for brain metastases. Another series published that year identified 30 patients who received hypofractionated radiotherapy, all of whom had undergone prior resection. 2 In this report, there were no patients with radiation necrosis in the group who had never received WBRT (20 patients), while 3 patients (30%) of the prior-WBRT group had treatment-related toxicity. Lastly, a recent study of 65 patients whose postsurgical cavities were treated with 25-30 Gy in 5 fractions found a radiation necrosis rate of 1.5%. 1 Taken as a whole, the presented literature suggests that the use of 30 Gy in 5 fractions to treat resection cavities for brain metastases is effective and offers minimal risk of toxicity, especially in a population that has never received intracranial radiotherapy. Despite this, the impact of this dose-fractionation schedule on toxicities like radiation necrosis in children with brain metastases warrants further investigation.
In summary, we describe a 9-year-old boy with 2 brain metastases from Ewing sarcoma treated with resection and adjuvant hypofractionated partial-brain radiation therapy to 30 Gy in 5 fractions, rather than WBRT. Eight months after radiation therapy, the patient experienced symptomatic treatment-related inflammatory changes within the high-dose region of the treatment field that was confirmed on MR spectroscopy, with rapid symptom resolution after receiving dexamethasone. There is no consensus in the literature, but recent reports suggest that MR spectroscopy and perfusion-weighted imaging have higher sensitivity and specificity than PET-CT in differentiating radiation necrosis from recurrent metastasis. 6 Biopsy remains the gold standard. Five months after this episode, new neurological symptoms prompted MR perfusion-weighted imaging, and the findings were suggestive of recurrence. A subsequent biopsy confirmed radiation necrosis with no evidence of disease. The patient was found to have resolving posttreatment changes with no evidence of disease as of his last follow-up 21 months after the presentation of his brain metastases. We demonstrate that hypofractionated partial-brain radiation therapy with limited margins is a reasonable approach following gross tumor resection, especially for pediatric patients who could potentially be spared the long-term neurocognitive side effects of WBRT. 
